Veru (VERU) Stock Price, News & Analysis

Company Overview

Veru Inc. is a biopharmaceutical company focused on developing medicines for obesity, metabolic disorders and cancer. Its development programs are designed to address weight management, preservation of muscle mass during weight loss and treatment of certain hormone-sensitive cancers.

The company’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being evaluated for its potential to promote or preserve lean muscle while supporting weight loss. Veru has also developed oncology candidates, including sabizabulin, an oral microtubule disruptor studied in cancer indications, and other hormone-directed therapies.

Veru was formerly known as The Female Health Company and historically developed and commercialized the FC2 Female Condom, a female-controlled barrier contraceptive and sexually transmitted infection prevention product distributed in the United States and international markets. The company adopted the Veru name as it expanded its focus toward pharmaceutical development. Mitchell S. Steiner, M.D., serves as the company’s chairman, president and chief executive officer.

Key Stats

• Today's Range: $2.50 to $2.56
• 50-Day Range: $2.21 to $2.80
• 52-Week Range: $2.05 to $7.33
• Volume: 78,215 shs
• Average Volume: 735,736 shs
• Market Capitalization: $42.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.50
• Consensus Rating: Hold

Veru Stock Analysis - MarketRank™

Veru scored higher than 44% of companies evaluated by MarketBeat, and ranked 597th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Veru has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Veru has a consensus price target of $24.50, representing about 875.3% upside from its current price of $2.51.

Amount of Analyst Coverage

Veru has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Veru are expected to decrease in the coming year, from ($1.07) to ($1.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veru is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veru is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Veru has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.30% of the float of Veru has been sold short.

Short Interest Ratio / Days to Cover

Veru has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Veru has recently increased by 11.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veru does not currently pay a dividend.

Dividend Growth

Veru does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: N/A

News Sentiment

Veru has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Veru this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

7 people have added Veru to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $4,842.00 in company stock, which represents 0.0113% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Veru insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,842.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/26/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VERU
• CIK: 863894
• Web: www.verupharma.com
• Phone: (312) 595-9123
• Fax: 312-595-9122
• Employees: 230
• Year Founded: 1896

Price Target and Rating

• Average Price Target for Veru: $24.50
• High Price Target: $25.00
• Low Price Target: $24.00
• Potential Upside/Downside: +878.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.58%
• Return on Assets: -35.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.42
• Quick Ratio: 4.42

Sales & Book Value

• Annual Sales: $16.89 million
• Price / Sales: 2.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.25 per share
• Price / Book: 2.00

Miscellaneous

• Outstanding Shares: 17,050,000
• Free Float: 14,629,000
• Market Cap: $42.71 million
• Optionable: Optionable
• Beta: -1.21